Suppr超能文献

腹膜透析患者在实现充分治疗方面的体表面积限制。

Body surface area limitations in achieving adequate therapy in peritoneal dialysis patients.

作者信息

Rocco M V

机构信息

Department of Internal Medicine, Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, North Carolina, USA.

出版信息

Perit Dial Int. 1996 Nov-Dec;16(6):617-22.

PMID:8981531
Abstract

OBJECTIVE

To estimate the maximal body surface area (BSA) at which anuric chronic peritoneal dialysis patients can achieve adequate peritoneal dialysis using a variety of continuous ambulatory peritoneal dialysis (CAPD) and cycler regimens. Adequate dialysis was defined as a creatinine clearance of either 60 L/week/1.73 m2 or 70 L/ week/1.73 m2.

DESIGN

Calculation of daily peritoneal creatinine clearances using standard formulas. For CAPD patients, creatinine clearance was calculated using published values for dialysate-to-plasma ratios for creatinine (D/P cr) measured over a 24-hour period and assuming a daily ultrafiltration rate of 1.5 to 2.0 L/day. For cycler patients, creatinine clearance was calculated for both one- and two-hour dwell volumes, using published values for D/P cr from the peritoneal equilibration test and assuming a daily ultrafiltration rate of 2.0 L/day. All clearances were corrected to a normalized body surface area of 1.73 m2.

RESULTS

For CAPD patients, 2-L dwell volumes can provide a weekly creatinine clearance of 60 L/week/1.73 m2 in patients with BSA < 1.45 m2 in the high transporter group and with BSA < 1.2 m2 in the low-average transporter group. Increasing dwell volume from 2.0 to 2.5 L increases these BSA limits in the four transport groups by 0.2-0.3 m2. Cycler therapy is not a viable option for patients in the low transporter group, and this therapy can achieve adequate creatinine clearances in patients in the low-average transport group only with large dwell volumes and in patients with BSA < 1.55 m2. However, in the high-average and high transporter groups, cycler therapy provides for superior creatinine clearances compared to CAPD patients using similar dwell volumes.

CONCLUSIONS

Adequate creatinine clearances in anuric patients are most likely to be achieved in patients with BSA > 2.0 m2 if they have high-average or high transport characteristics and are receiving cycler therapy with large dwell volumes and at least one daytime dwell. However, adequate creatinine clearances may be difficult to achieve in anuric patients who have a large BSA and a low or low-average transport type, regardless of peritoneal dialysis modality. These patients should be considered for either high-dose peritoneal dialysis (multiple daytime and nighttime exchanges) or hemodialysis therapy.

摘要

目的

评估无尿的慢性腹膜透析患者使用各种持续性非卧床腹膜透析(CAPD)和循环腹膜透析方案时,能够实现充分腹膜透析的最大体表面积(BSA)。充分透析定义为肌酐清除率达到60L/周/1.73m²或70L/周/1.73m²。

设计

使用标准公式计算每日腹膜肌酐清除率。对于CAPD患者,肌酐清除率通过已发表的24小时内测得的透析液与血浆肌酐比值(D/P cr)值计算得出,并假设每日超滤率为1.5至2.0L/天。对于循环腹膜透析患者,根据腹膜平衡试验中已发表的D/P cr值,分别计算1小时和2小时留存量的肌酐清除率,并假设每日超滤率为2.0L/天。所有清除率均校正至标准化体表面积1.73m²。

结果

对于CAPD患者,在高转运组中,BSA < 1.45m²的患者以及在低-平均转运组中,BSA < 1.2m²的患者,2L留存量可提供每周60L/周/1.73m²的肌酐清除率。将留存量从2.0L增加至2.5L,在四个转运组中,这些BSA限制增加0.2 - 0.3m²。对于低转运组患者,循环腹膜透析疗法不是一个可行的选择,并且该疗法仅在留存量较大且BSA < 1.55m²的低-平均转运组患者中能实现充分的肌酐清除率。然而,在高-平均转运组和高转运组中,与使用类似留存量的CAPD患者相比,循环腹膜透析疗法能提供更高的肌酐清除率。

结论

如果无尿患者具有高-平均或高转运特征,并接受大留存量且至少有一次日间留存的循环腹膜透析疗法,那么BSA > 2.0m²的患者最有可能实现充分的肌酐清除率。然而,无论采用何种腹膜透析方式,对于BSA较大且转运类型为低或低-平均的无尿患者,可能难以实现充分的肌酐清除率。这些患者应考虑接受高剂量腹膜透析(多次日间和夜间交换)或血液透析治疗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验